We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+21.98%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$679M
AUM Growth
+$8.14M
Cap. Flow
+$879K
Cap. Flow %
0.13%
Top 10 Hldgs %
38.68%
Holding
124
New
21
Increased
25
Reduced
15
Closed
25

Top Buys

Rank Stock Value
1
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$18.7M
2
IFRX icon
InflaRx
IFRX
+$13M
3
VSTM icon
Verastem
VSTM
+$7.91M
4
AVIR icon
Atea Pharmaceuticals
AVIR
+$7.58M
5
ELEV
Elevation Oncology
ELEV
+$6.86M

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$21.5M
2
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$9.81M
3
BLUE
bluebird bio
BLUE
+$9.14M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.01M
5
MRNA icon
Moderna
MRNA
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.72%
2 Financials 6.8%
3 Real Estate 0.3%
4 Consumer Discretionary 0.15%
5 Utilities 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COF icon
26
Capital One
COF
$135B
$8.75M 1.29%
80,000
-20,000
-20% -$2M
THRD
27
DELISTED
Third Harmonic Bio
THRD
$8.66M 1.27%
1,800,000
– –
VSTM icon
28
Verastem
VSTM
$519M
$8.48M 1.25%
+1,140,000
New +$7.91M
AMRN
29
Amarin Corp
AMRN
$301M
$8.45M 1.24%
355,000
+85,000
+31% +$2.18M
KNSA icon
30
Kiniksa Pharmaceuticals
KNSA
$5.97B
$8.45M 1.24%
600,000
– –
IONS icon
31
Ionis Pharmaceuticals
IONS
$9.06B
$8.21M 1.21%
200,000
– –
ELEV
32
DELISTED
Elevation Oncology
ELEV
$6.08M 0.9%
4,000,000
+2,600,000
+186% +$6.86M
BIO icon
33
Bio-Rad Laboratories Class A
BIO
$9.16B
$6.07M 0.89%
16,000
– –
ACET icon
34
Adicet Bio
ACET
$74.2M
$6.03M 0.89%
154,972
-2,528
-2% -$223K
QNCX icon
35
Quince Therapeutics
QNCX
$28.9M
$5.44M 0.8%
18,066
-34
-0.2% -$10.6K
LENZ
36
LENZ Therapeutics
LENZ
$164M
$5.42M 0.8%
297,946
+8,165
+3% +$163K
CGEM icon
37
Cullinan Oncology
CGEM
$1.16B
$4.84M 0.71%
450,000
-50,000
-10% -$531K
ADMA icon
38
ADMA Biologics
ADMA
$2.25B
$4.65M 0.68%
+1,260,000
New +$4.67M
C icon
39
Citigroup
C
$224B
$4.6M 0.68%
100,000
– –
DNTH icon
40
Dianthus Therapeutics
DNTH
$6.15B
$4.59M 0.68%
378,750
+625
+0.2% +$7.11K
PYXS icon
41
Pyxis Oncology
PYXS
$238M
$4.58M 0.67%
1,787,775
-693,887
-28% -$2.2M
ADAP
42
DELISTED
Adaptimmune Therapeutics
ADAP
$4.52M 0.67%
+4,887,238
New +$5.83M
RAIN
43
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$4.49M 0.66%
+3,740,341
New +$18.7M
GNFT
44
DELISTED
Genfit
GNFT
$4.37M 0.64%
1,234,436
+21,921
+2% +$90.4K
BOLT icon
45
Bolt Biotherapeutics
BOLT
$7.44M
$4.27M 0.63%
166,690
+85,312
+105% +$2.71M
ENZ
46
DELISTED
Enzo Biochem, Inc.
ENZ
$4.23M 0.62%
2,300,000
– –
NVCR icon
47
NovoCure
NVCR
$1.83B
$4.15M 0.61%
+100,000
New +$6.21M
ASLN
48
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$4.12M 0.61%
141,009
-4,654
-3% -$144K
DVAX
49
DELISTED
Dynavax Technologies
DVAX
$3.88M 0.57%
300,000
– –
VBTX
50
DELISTED
Veritex Holdings
VBTX
$3.77M 0.55%
210,000
+100,000
+91% +$1.78M
1
2
3 4 5

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Tang Capital Management held 124 positions worth $679M, up 1.2% from $671M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tang Capital Management's Q2 2023 filing shows 21 new, 25 increased, 15 reduced and 25 closed positions. Its largest new stake was Rain Oncology Inc. Common Stock: 3,740,341 shares worth $4.49M. The largest sale was Novo Nordisk, an estimated $21.5M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Financials and Real Estate.

  • Tang Capital Management's largest Q2 2023 buy was Rain Oncology Inc. Common Stock: 3,740,341 shares worth $4.49M.
  • Tang Capital Management added most to Atea Pharmaceuticals in Q2 2023, an estimated $7.58M increase.
  • Tang Capital Management's biggest Q2 2023 reduction was bluebird bio, cutting an estimated $9.14M.
  • Tang Capital Management fully exited Novo Nordisk in Q2 2023, selling an estimated $21.5M.
  • Tang Capital Management's ten largest holdings make up 39% of its $679M portfolio in Q2 2023.
  • Tang Capital Management opened 21 new positions and closed 25 in Q2 2023.
  • Tang Capital Management's portfolio value rose 1.2% quarter-over-quarter to $679M.

Based on Tang Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.